Orexo strengthens its subsidiary Kibion by recruiting Petter Bäckgren as CEO

Orexo strengthens its subsidiary Kibion by recruiting Petter Bäckgren as
CEO

Uppsala, Sweden, October 27, 2010 - Orexo AB (STO: ORX) announces that
Petter Bäckgren has been appointed as the new CEO for its diagnostic
subsidiary Kibion.  Petter has excellent experience in sales and
marketing and general management within the pharma and diagnostic
sectors, both in the Nordic countries and internationally.

Petter Bäckgren has since 2009 been working as General Manager of the
clinical diagnostics business at DiaSorin for the UK, Ireland and Nordic
region. Petter has also previously worked for Novartis, where he held
several positions including Regional Business Manager and Head of Sales
in General Medicine. Petter has demonstrated his ability to increase
sales and his strong customer focus.

Petter Bäckgren will commence his position on November 15, replacing
acting CEO for Kibion, Erik Bergman, who will be leaving the company to
pursue other interests.

Torbjörn Bjerke, President and CEO of Orexo comments:
“We are delighted to have been able to recruit Petter Bäckgren to our
subsidiary Kibion. His solid experience and background will contribute
to Kibion's continued growth and value increase. I would also like to
thank Erik Bergman for his contributions to Kibion both as CFO and as
acting CEO, and wish him all the best in his future endeavours.”

Contact details:
Torbjörn Bjerke, President and CEO, Orexo AB
Tel: +46 (0)708 66 19 90
Email: torbjorn.bjerke@orexo.com (torbjorn.bjerke@orexo.com)

Robin Wright, EVP and CFO, Orexo AB
Tel: +44 7720 300025
Email: robin.wright@orexo.com (robin.wright@orexo.com)

Notes to Editors

About Kibion
Kibion AB, a wholly owned subsidiary of Orexo, is a growing dynamic
company and world-leading supplier of breath tests to diagnose the
stomach ulcer bacterium Helicobacter pylori (Hp). Kibion has currently
has two products to diagnose Helicobacter pylori - Diabact® UBT and
Heliprobe® System. Kibion's products are sold in some 50 countries,
primarily in Europe, the Middle East, Asia and Latin America. The
company was founded in 2005 and its operations are based in Uppsala,
Sweden.

About Orexo
Orexo is a pharmaceutical company focusing on developing treatments for
pain and inflammation. Orexo is developing proprietary products based on
its proven reformulation technologies, targeted at the Specialty
Pharmaceutical market. Orexo intends to commercialise some of these
products itself in one or more major markets. Its development activity
builds on Orexo's core competences in R&D, which have previously
resulted in several successful products, currently out-licensed through
worldwide partnership agreements to larger pharmaceutical companies.
Today, Orexo has four products on the market of which AbstralTM is a
leading product for the treatment of breakthrough pain in cancer
patients in most of Europe.
Orexo also has three significant partnerships with major pharmaceutical
companies for research and development programs: discovery stage
collaborations with Ortho-McNeil Janssen and Janssen Pharmaceutica in
respiratory inflammation and with Boehringer Ingelheim for pain, both
within the arachidonic acid cascade and a clinical stage development
agreement with Novartis in gastrointestinal disorders.
Orexo's head office is located in Uppsala, Sweden.

More information can be found at www.orexo.com (http://www.orexo.com/).

Note:
This is information that Orexo AB (publ.) is required to disclose
pursuant to the Swedish Securities Markets Act. The information was
provided for public release on October 27, 2010 at 12:00 a.m. CET.